NCT02377180

Brief Summary

There is currently no specific diagnostic test for primary muscular pain. The present study investigates whether selective blockade of the suprascapular nerve can effectively abolish experimental pain arising from the supraspinatus muscle. Experimental muscle pain is induced by intramuscular injection of capsaicin, an alkaloid from red chili peppers. The study consists of three parts:

  1. 1.to describe the development, time course and intensity of capsaicin-induced muscle pain
  2. 2.to evaluate the effectiveness of suprascapular nerve block against capsaicin-induced muscle pain
  3. 3.to compare suprascapular nerve block and direct intramuscular local anesthetic infiltration for their effectiveness in capsaicin-induced muscle pain

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
72

participants targeted

Target at P75+ for not_applicable healthy

Timeline
Completed

Started Sep 2014

Longer than P75 for not_applicable healthy

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

September 1, 2014

Completed
5 months until next milestone

First Submitted

Initial submission to the registry

February 11, 2015

Completed
20 days until next milestone

First Posted

Study publicly available on registry

March 3, 2015

Completed
1.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2016

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2016

Completed
Last Updated

January 18, 2017

Status Verified

January 1, 2017

Enrollment Period

2.3 years

First QC Date

February 11, 2015

Last Update Submit

January 16, 2017

Conditions

Keywords

musculoskeletal painregional anesthesiadiagnostic nerve blockintramuscular capsaicinreferred painhyperalgesiaexperimental paincentral hypersensitivityhuman experimental pain

Outcome Measures

Primary Outcomes (1)

  • Intensity of shoulder pain on numeric rating scale

    two hours

Secondary Outcomes (2)

  • Pressure pain thresholds

    two hours

  • Area of referred pain

    two hours

Study Arms (3)

Part 1

EXPERIMENTAL

Intramuscular injection of capsaicin for the study of pain and hyperalgesia

Procedure: Intramuscular capsaicin injection

Part 2

ACTIVE COMPARATOR

Pain arising from supraspinatus muscle vs. pain arising from trapezius muscle. Nerve block is only expected to be effective in the former.

Procedure: Suprascapular nerve block

Part 3

ACTIVE COMPARATOR

Suprascapular nerve block vs. intramuscular local anesthetic against pain arising from the supraspinatus muscle.

Procedure: Local anesthetic infiltration

Interventions

Intramuscular injection of capsaicin: 50 mcg/0.5 ml

Part 1

Injection of capsaicin 50 mcg/0.5 ml into the supraspinatus or trapezius muscle in randomized order, followed by suprascapular nerve block (ultrasound-guided) using Lidocaine 1%; nerve block is expected to be effective only in pain arising from the supraspinatus muscle. Trapezius pain serves as control condition. Evaluates the diagnostic validity of suprascapular nerve block for muscle pain.

Part 2

Injection of capsaicin 50 mcg/0.5 ml into the supraspinatus muscle in two different sessions; suprascapular nerve block in one session and intramuscular local anesthetic infiltration in one session (in randomized order) using Lidocaine 1%; the aim is to investigate which procedure provides faster and more efficient pain relief. Compares effectivity of suprascapular nerve block vs. intramuscular local anesthetic infiltration.

Part 3

Eligibility Criteria

Age18 Years - 80 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Age 18-80 years
  • Written informed consent

You may not qualify if:

  • Any acute pain at the moment of testing
  • Intake of analgesics 24hours before testing
  • Intake of antidepressants, anticonvulsants or benzodiazepines
  • Allergy to local anesthetic or skin disinfectant
  • Pregnancy or breast-feeding

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University Department of Anesthesiology and Pain Therapy,Inselspital Bern

Bern, Canton of Bern, 3010, Switzerland

Location

Related Publications (3)

  • Graven-Nielsen T, Gibson SJ, Laursen RJ, Svensson P, Arendt-Nielsen L. Opioid-insensitive hypoalgesia to mechanical stimuli at sites ipsilateral and contralateral to experimental muscle pain in human volunteers. Exp Brain Res. 2002 Sep;146(2):213-22. doi: 10.1007/s00221-002-1169-7. Epub 2002 Jul 13.

    PMID: 12195523BACKGROUND
  • Witting N, Svensson P, Gottrup H, Arendt-Nielsen L, Jensen TS. Intramuscular and intradermal injection of capsaicin: a comparison of local and referred pain. Pain. 2000 Feb;84(2-3):407-12. doi: 10.1016/s0304-3959(99)00231-6.

    PMID: 10666547BACKGROUND
  • Siegenthaler A, Moriggl B, Mlekusch S, Schliessbach J, Haug M, Curatolo M, Eichenberger U. Ultrasound-guided suprascapular nerve block, description of a novel supraclavicular approach. Reg Anesth Pain Med. 2012 May-Jun;37(3):325-8. doi: 10.1097/AAP.0b013e3182409168.

    PMID: 22222688BACKGROUND

MeSH Terms

Conditions

Musculoskeletal PainPain, ReferredHyperalgesia

Condition Hierarchy (Ancestors)

Muscular DiseasesMusculoskeletal DiseasesPainNeurologic ManifestationsSigns and SymptomsPathological Conditions, Signs and SymptomsSomatosensory DisordersSensation DisordersNervous System Diseases

Study Officials

  • Michele Curatolo, M.D., Ph.D.

    Department of Anesthesiology and Pain Therapy, University of Washington, Seattle WA, USA

    STUDY CHAIR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
PARTICIPANT
Purpose
BASIC SCIENCE
Intervention Model
CROSSOVER
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

February 11, 2015

First Posted

March 3, 2015

Study Start

September 1, 2014

Primary Completion

December 1, 2016

Study Completion

December 1, 2016

Last Updated

January 18, 2017

Record last verified: 2017-01

Locations